HemoGenyx, LLC
HemoGenyx is a preclinical-stage biotechnology company focused on the discovery, development and commercialisation of novel therapies and treatments for blood diseases, like leukemia and lymphoma. HemoGenyx Team: Vladislav Sandler
Read MoreParkside Scientific
New York City based Parkside Scientific develops novel “best-in-class” small molecule drugs that target bromodomain (BrD) proteins for epigenetic control of gene transcription in cancers and inflammatory disorders. Parkside…
Read MoreLucerna, Inc.
At Lucerna, we are developing new sets of research tools to study and exploit RNA the same way fluorescent proteins did for the protein field. Lucerna Team: Karen Wu
Read MoreMirimus
Mirimus is engaged in the design, development and pioneering of new genome editing technologies to develop animal models that are crucial for the preclinical evaluation of new therapeutics. Mirimus Team: Prem Premsrirut
Read MoreNovyx Technologies
A cost-effective hydrogel dressing for chronic wounds, which enhances wound healing, reduces inflammation, risk of infection and pain, as well as provides comfort during use. Novyx Technologies Team: Waleed Abdel-Naby,…
Read MoreTaithera, Inc.
Aithera is a revolutionary nanomedicine bone targeted drug delivery controlled release platform technology for the treatment of musculoskeletal conditions focused initially on fracture healing & bone cancer (osteosarcoma is our…
Read MoreMassive Bio
Massive Bio provides cutting-edge concierge advisory services for precision oncology to cancer patients treated at community practices. Massive Bio Team: Selin Kurnaz, PhD. – CEO
Read MoreAision Biotechnologies
Prophylactic drugs that protect against depression and PTSD in a vaccine-like fashion. Rebecca Brachman, Co-Founder Christine Denny, PhD, Co-Founder
Read MoreJotteq
Jot is a new kind of eye drop dispenser that is safe and easy to use. My objective is to bring it to market Jotteq Team: Nigel Kelly
Read MoreIchor Biologics
A validated platform for the isolation of human monoclonal antibodies (mAbs), which neutralize emerging and re-emerging infectious diseases. Ichor Biologics Team: Raymond Alvarez Justin Ring
Read More